Ser219
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser219  -  AP-2 alpha (human)

Site Information
CSVPGRLsLLSsTsk   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 25581601

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 2 ) , immunoprecipitation ( 1 ) , mutation of modification site ( 2 ) , phospho-antibody ( 1 ) , western blotting ( 1 , 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 2 ) , leukocyte-blood ( 1 ) , vascular smooth muscle cell ('muscle, smooth') ( 1 ) , VSMC-aorta ( 2 )

Upstream Regulation
Putative in vivo kinases:
AMPKA2 (human) ( 2 )
Kinases, in vitro:
AMPKA2 (human) ( 2 )
Treatments:
angiotensin_2 ( 2 ) , aspirin ( 1 ) , compound_C ( 2 ) , nicotine ( 2 ) , siRNA ( 2 )

Downstream Regulation
Effects of modification on AP-2 alpha:
activity, induced ( 1 ) , molecular association, regulation ( 1 , 2 )
Effects of modification on biological processes:
transcription, induced ( 1 , 2 )
Induce interaction with:
DNA ( 1 , 2 )

References 

1

Yang JJ, et al. (2016) Activation of activator protein 2 alpha by aspirin alleviates atherosclerotic plaque growth and instability in vivo. Oncotarget 7, 52729-52739
27391154   Curated Info

2

Wang S, et al. (2012) Activation of AMP-activated protein kinase α2 by nicotine instigates formation of abdominal aortic aneurysms in mice in vivo. Nat Med 18, 902-10
22561688   Curated Info